• Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

  • 2024/09/10
  • 再生時間: 9 分
  • ポッドキャスト

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

  • サマリー

  • Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.


    Speaker 3: (00:32)
    Would you tell us a little bit about yourself and your history with this testing?

    Speaker 3: (01:25)
    Would you tell us a little more about this assay?

    Speaker 3: (04:57)
    Which patients should have this testing and when should it be performed?

    Speaker 3: (05:30)
    What alternative tests exist and how do they compare?

    Speaker 3: (06:28)
    How are the results used in patient care?

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.


Speaker 3: (00:32)
Would you tell us a little bit about yourself and your history with this testing?

Speaker 3: (01:25)
Would you tell us a little more about this assay?

Speaker 3: (04:57)
Which patients should have this testing and when should it be performed?

Speaker 3: (05:30)
What alternative tests exist and how do they compare?

Speaker 3: (06:28)
How are the results used in patient care?

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.に寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。